Glycerofosforzuur (=disodium-glycerophospate)
Generic name
Glycerofosforzuur (=disodium-glycerophospate)
Brand name
ATC Code
B05XA14
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.
No pharmacokinetical data is available for infants, however with the recommended dosage hyperphosphataemia is unlikely.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Hypophosphataemia |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Hypernatraemia, hyperphosphataemia, shock or dehydration.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Glycophos should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly. Be aware that glycophos contains sodium.
Glycophos must not be given undiluted.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
I.V. SOLUTION ADDITIVES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Electrolyte solutions | ||
|---|---|---|
| B05XA07 | ||
| B05XA19 | ||
| B05XA31 | ||
| B05XA06 | ||
| Amino acids | ||
|---|---|---|
| B05XB01 | ||
| Vitamins | ||
|---|---|---|
| B05XC | ||
| VITAMINS | ||
|---|---|---|
| B05XC | ||
Reference
- Fresenius Kabi Nederland BV, SmPC Glycophos (RVG 16431) 17-09-2018, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
